SuperworthMettler-Toledo International Inc. MTD
Medical - Diagnostics & Research, Healthcare
$1,526.94
−0.43%
- Market cap
- $30.6B
- PE
- 34.5×
- 10y median 36.5×
- Forward PE
- Price to sales
- 7.4×
- EV/EBIT
- 28.1×
- Revenue, 12 months
- $4.1B
- +7% on a year ago
- Net margin
- 21.9%
- Free cash flow yield
- 2.8%
Mettler-Toledo International trades at 34.5× trailing earnings, near its ten-year median. Revenue was $4.1B over the last twelve months, up 7% on a year earlier with a 22% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $935M | $925.9M | $946.8M | $954.5M | $1B+12% | $883.7M−5% | $983.2M+4% | $1B+8% | $1.1B+8% | $947.1M+7% | $1B+5% | |
| Cost of revenue | $401.4M | $396M | $399.3M | $400.3M | $424M+6% | $375.1M−5% | $420.9M+5% | $440.3M+10% | $474M+12% | $410.9M+10% | $396.5M−6% |
| Gross profit | $551.6M | $548.1M | $565.7M | $572.5M | $639.3M+16% | $525.9M−4% | $579.9M+3% | $609.5M+7% | $675.4M+6% | $555.8M+6% | $650.2M+12% |
| R&D | $46.4M | $46.4M | $45.8M | $47.1M | $50.1M+8% | $46.3M−0% | $49.3M+8% | $51.1M+9% | $52.6M+5% | $51.3M+11% | $53M+8% |
| SG&A | $223.4M | $234.4M | $235.8M | $228.8M | $237.3M+6% | $242.8M+4% | $247.3M+5% | $248.4M+9% | $259.8M+10% | $258.3M+6% | $263.3M+7% |
| $263.7M | $249.1M | $265.9M | $278.3M | $333.7M+27% | $219.5M−12% | $265.7M−0% | $289.9M+4% | $343.3M+3% | $226.6M+3% | $314.5M+18% | |
| Interest expense | $19.7M | $19.2M | $18.9M | $18.6M | $17.9M−9% | $16.7M−13% | $16.8M−12% | $17.7M−5% | $17.4M−3% | $17M+2% | $17.2M+3% |
| Pre-tax income | $232.6M | $220.5M | $243.2M | $259M | $314.5M+35% | $201.9M−8% | $248.7M+2% | $269.2M+4% | $329.1M+5% | $209.7M+4% | $289.4M+16% |
| $47.8M | $43M | $21.4M | $47.4M | $62.2M+30% | $38.4M−11% | $46.3M+117% | $51.7M+9% | $43.3M−30% | $40.2M+5% | $56.5M+22% | |
| Net income | $184.8M | $177.5M | $221.8M | $211.5M | $252.3M+37% | $163.6M−8% | $202.3M−9% | $217.5M+3% | $285.8M+13% | $169.5M+4% | $232.9M+15% |
| $8.52 | $8.24 | $10.37 | $9.96 | $11.96+40% | $7.81−5% | $9.76−6% | $10.57+6% | $13.98+17% | $8.33+7% | $11.55+18% | |
| 21.7M | 21.5M | 21.4M | 21.2M | 21.1M−3% | 20.9M−3% | 20.7M−3% | 20.6M−3% | 20.4M−3% | 20.3M−3% | 20.2M−3% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Medical - Diagnostics & Research within ten times Mettler-Toledo International's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MTDMettler-Toledo International Inc. | $30.6B | 34.5× | 36.5× | 7.4× | +7% | 21.9% | |
| LHLabcorp Holdings Inc. | $25.5B | 25.8× | 21.9× | 1.8× | +6% | 7.0% | |
| DGXQuest Diagnostics Incorporated | $25.3B | 24.1× | 19.1× | 2.2× | +10% | 9.2% | |
| ILMNIllumina, Inc. | $39.5B | 49.9× | 50.6× | 9.0× | +5% | 18.4% | |
| IDXXIDEXX Laboratories, Inc. | $40.4B | 35.6× | 54.8× | 8.8× | +13% | 25.0% | |
| WATWaters Corporation | $42B | 109× | 29.3× | 9.2× | +52% | 3.6% | |
| IQVIQVIA Holdings Inc. | $42.2B | 32.0× | 35.0× | 2.5× | +8% | 8.1% | |
| AAgilent Technologies, Inc. | $47.2B | 33.3× | 32.4× | 6.5× | +9% | 19.5% | |
| DHRDanaher Corporation | $151.8B | 38.8× | 36.4× | 6.1× | +5% | 15.9% | |
| TMOThermo Fisher Scientific Inc. | $239.9B | 35.6× | 32.8× | 5.3× | +7% | 15.0% | |
| Peer median | $42B | 35.6× | 32.8× | 6.1× | +8% | 15.0% |
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .